Alvotech, Lotus Strike $150 Million Biosimilar Deal for U.S. and 8 Asian Markets

2 articles · Updated · Yahoo Finance · Aug 21

Up to $150 million in upfront and milestone payments will go to Alvotech under a new licensing and commercialization pact with Lotus for AVT34 and AVT87.
The deal covers proposed biosimilars to AstraZeneca's Imfinzi and Roche's Hemlibra, two biologics that generated about $6.1 billion and $5.8 billion respectively in 2025 sales.
In the United States, the agreement is semi-exclusive: Alvotech keeps the right to sell both products directly, while Lotus will market them through its U.S. subsidiary Alvogen.
Across Asia, Lotus gets exclusive commercialization rights in eight markets, while Alvotech remains responsible for development, U.S. marketing authorizations and product supply for all territories.
Alvotech said the arrangement marks its first chance to participate directly in future U.S. commercialization, potentially letting it capture more value from its biosimilar platform.